Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Co-administered ZF2001 and Tetravalent Influenza Vaccine
NCT05107375Phase 3Completed
- Sponsor
- Zhifei Biological
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ZF2001 in coronavirus disease 2019 (COVID-19) and influenza (2 arms), sponsored by Zhifei Biological. Primary endpoint: Immunogenicity Evaluation. Started Sep 2021; status: completed.
02
Drugs
ZF2001
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT05107375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107375.